Statistics from Altmetric.com
The 2017, the Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina (ORBITA) trial by Al-Lamee et al 1 was the first double-blind, randomised, sham-controlled trial to investigate the role of percutaneous coronary intervention (PCI) for the treatment of stable angina. It showed no significant difference in exercise tolerance between patients treated with a sham procedure (placebo) and with PCI. Further, patients who underwent PCI had no improvements in other exercise outcomes, nor with any patient-reported endpoints. The results from the ORBITA trial have important implications for clinical practice and research.
The ORBITA trial questioned what has now become routine clinical practice, namely PCI for patients with stable angina. The results suggest that patients who undergo PCI for stable angina accept a small, but not insignificant, risk of harm for no benefit. It is hard to imagine a scenario where a fully informed patient would …
Contributors DRW and JWO contributed equally.
Competing interests None declared.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.